Misplaced Pages

Vericel

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
American biopharmaceutical company For the gymnyst, see Cassy Vericel.
Vericel Corporation
FormerlyAastrom Biosciences, Inc.
Company typePublic
Traded asNasdaqVCEL
Russell 2000 component
S&P 600 component
IndustryBiotechnology
Founded1989; 36 years ago (1989) in Ann Arbor, Michigan, United States
HeadquartersCambridge, Massachusetts, United States
Number of locations2
Key people
  • Nick Colangelo (CEO)
  • Daniel Orlando (COO)
  • Gerard Michel (CFO)
Products
  • MACI
  • Epicel
  • Carticel

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.

In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.

In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.

References

  1. ^ Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.
Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it.

Categories:
Vericel Add topic